Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout - Pharmaceutical Technology

The non-opioid pain field is attracting interest as experts sound the alarm on dependency issues linked to long-term opioid-based pain management. The non-opioid pain space is attracting increasing attention as experts sound the alarm on dependency issues linked to long-term opioid-based pain management. Viatris will acquire the rights to Exparel and Zilretta if this acquisition goes ahead. Credit: Dragana Gordic / Shutterstock.com. California-based healthcare company Viatris has inked a billion-dollar deal to acquire Pacira BioSciences and its non-opioid pain management therapies – allowing the company to enter a market attracting growing attention amid the ongoing effects from the opioid crisis…

Source: Pharmaceutical Technology